- Conditions
- Atrophy, Geographic
- Interventions
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- 400 µg Brimonidine Implant, Sham
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
- Conditions
- Geographic Atrophy
- Interventions
- Lampalizumab, Sham
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- PRIMA
- Device
- Lead sponsor
- Science Corporation
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Miami, Florida • Pittsburgh, Pennsylvania
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 78
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
- Interventions
- Not listed
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration, AMD
- Interventions
- OT-551 antioxidant eye drop
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration, Age-related, Geographic Atrophy
- Interventions
- BI 771716, Pegcetacoplan, Sham comparator to BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 68,563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
- Interventions
- Arm 1
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Geographic Atrophy
- Interventions
- STL303, Placebo
- Drug
- Lead sponsor
- Sitala Bio LTD
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 20
- States / cities
- Bakersfield, California • Beverly Hills, California • Oakland, California + 16 more
- Conditions
- Geographic Atrophy
- Interventions
- SAR446597, Sham Comparator
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 15
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Gainesville, Florida + 10 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- CTx001
- Genetic
- Lead sponsor
- Complement Therapeutics
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Nidek MP-3
- Device
- Lead sponsor
- Doheny Image Reading Center
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Geographic Atrophy
- Interventions
- RO7171009
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Bakersfield, California • Mountain View, California • Sacramento, California + 10 more
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration
- Interventions
- OcuMet Beacon
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
- Interventions
- Not listed
- Lead sponsor
- Optos, PLC
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
- Conditions
- Dry Macular Degeneration
- Interventions
- SS-OCT imaging
- Device
- Lead sponsor
- Boston Image Reading Center
- Industry
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
- Interventions
- Metformin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 12
- States / cities
- Davis, California • Palo Alto, California • Sacramento, California + 7 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Iptacopan (LNP023), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 22
- States / cities
- Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- i-Lumen AMD
- Device
- Lead sponsor
- i-Lumen Scientific AUS PTY LTD
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Manchester, Connecticut • Lemont, Illinois • Reno, Nevada + 2 more
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Carl Zeiss Meditec, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Oakland, California • Jackson, Michigan
- Conditions
- Geographic Atrophy of the Macula, Macular Degeneration
- Interventions
- AVD-104, Avacincaptad
- Drug
- Lead sponsor
- Aviceda Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 56
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 50 more
- Conditions
- Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy, Pathological Conditions, Anatomical
- Interventions
- Dapagliflozin, Matching Placebo
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri